Agenus Inc Stock Performance
| AGEN Stock | USD 3.74 0.16 4.10% |
Agenus has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.63, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Agenus will likely underperform. Agenus Inc right now shows a risk of 6.49%. Please confirm Agenus Inc potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Agenus Inc will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Agenus Inc are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Agenus may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
Actual Historical Performance (%)
One Day Return (4.10) | Five Day Return 2.19 | Year To Date Return 21.04 | Ten Year Return (96.14) | All Time Return (99.95) |
Last Split Factor 1:20 | Last Split Date 2024-04-12 |
1 | Acquisition by Garo Armen of 1502 shares of Agenus at 10.86 subject to Rule 16b-3 | 11/08/2024 |
2 | Agenus Stock Dips Amid Financial Performance and Industry Trends | 11/14/2024 |
3 | Agenus Stock Drops 5.50 percent Amid Biotech Sector Decline | 12/03/2024 |
4 | Tanner Pharma erweitert durch Partnerschaft mit Agenus den weltweiten Zugang zu Botensilimab und Balstilimab | 12/12/2024 |
5 | Acquisition by Garo Armen of 5347 shares of Agenus at 3.05 subject to Rule 16b-3 | 12/13/2024 |
6 | Agenus Stock Plummets 5.08 percent Amidst Mixed Ratings | 12/16/2024 |
7 | Agenus Announces Five Presentations at ASCO GI Highlighting BOTBAL Activity Across Colorectal and Gastric Cancers | 12/18/2024 |
8 | Acquisition by Garo Armen of 5931 shares of Agenus at 2.75 subject to Rule 16b-3 | 12/27/2024 |
9 | Acquisition by Hirsch Susan B of 6416 shares of Agenus subject to Rule 16b-3 | 12/31/2024 |
10 | Acquisition by Wright Timothy of 2532 shares of Agenus subject to Rule 16b-3 | 01/02/2025 |
11 | Acquisition by Garo Armen of 1040 shares of Agenus at 15.69 subject to Rule 16b-3 | 01/06/2025 |
12 | 960 Mn Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine - Global Forecast to 2029 with GSK, Seppic, Croda, SPI Pharma, Phibro Animal Health, Agen... | 01/08/2025 |
13 | Acquisition by Garo Armen of 4777 shares of Agenus at 3.12 subject to Rule 16b-3 | 01/10/2025 |
14 | SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development | 01/21/2025 |
15 | Acquisition by Garo Armen of 4169 shares of Agenus at 3.57 subject to Rule 16b-3 | 01/24/2025 |
16 | SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development | 01/30/2025 |
17 | Agenus Is Attractively Priced Despite Fast-paced Momentum | 02/06/2025 |
| Begin Period Cash Flow | 181.3 M |
Agenus |
Agenus Relative Risk vs. Return Landscape
If you would invest 390.00 in Agenus Inc on November 9, 2024 and sell it today you would lose (16.00) from holding Agenus Inc or give up 4.1% of portfolio value over 90 days. Agenus Inc is currently generating 0.1358% in daily expected returns and assumes 6.4861% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Agenus, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Agenus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Agenus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Agenus Inc, and traders can use it to determine the average amount a Agenus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0209
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | AGEN | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.49 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Agenus is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Agenus by adding it to a well-diversified portfolio.
Agenus Fundamentals Growth
Agenus Stock prices reflect investors' perceptions of the future prospects and financial health of Agenus, and Agenus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Agenus Stock performance.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (1.33) % | ||||
| Current Valuation | 125.69 M | ||||
| Shares Outstanding | 23.61 M | ||||
| Price To Earning | 10.52 X | ||||
| Price To Book | 218.61 X | ||||
| Price To Sales | 0.55 X | ||||
| Revenue | 156.31 M | ||||
| Gross Profit | (28.68 M) | ||||
| EBITDA | (145.92 M) | ||||
| Net Income | (245.76 M) | ||||
| Cash And Equivalents | 218.23 M | ||||
| Cash Per Share | 0.72 X | ||||
| Total Debt | 350.25 M | ||||
| Debt To Equity | 5.88 % | ||||
| Current Ratio | 1.45 X | ||||
| Book Value Per Share | (13.48) X | ||||
| Cash Flow From Operations | (224.2 M) | ||||
| Earnings Per Share | (11.02) X | ||||
| Market Capitalization | 88.31 M | ||||
| Total Asset | 313.91 M | ||||
| Retained Earnings | (1.96 B) | ||||
| Working Capital | (143.48 M) | ||||
| Current Asset | 63.4 M | ||||
| Current Liabilities | 9.97 M | ||||
About Agenus Performance
By examining Agenus' fundamental ratios, stakeholders can obtain critical insights into Agenus' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Agenus is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 29.43 | 27.96 | |
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (3.16) | (3.00) | |
| Return On Assets | (0.90) | (0.95) | |
| Return On Equity | 1.38 | 1.45 |
Things to note about Agenus Inc performance evaluation
Checking the ongoing alerts about Agenus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Agenus Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Agenus Inc had very high historical volatility over the last 90 days | |
| Agenus Inc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 156.31 M. Net Loss for the year was (245.76 M) with loss before overhead, payroll, taxes, and interest of (28.68 M). | |
| Agenus Inc currently holds about 218.23 M in cash with (224.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72. | |
| Latest headline from zacks.com: Agenus Is Attractively Priced Despite Fast-paced Momentum |
- Analyzing Agenus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Agenus' stock is overvalued or undervalued compared to its peers.
- Examining Agenus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Agenus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Agenus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Agenus' stock. These opinions can provide insight into Agenus' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.